Emerging Technologies In Aseptic Processing: Hype Vs. Operational Reality

By Juergen Metzger, Pharma-Technology-Consulting LLC

In recent years, robotics, gloveless isolators, and fully closed aseptic systems have become some of the most discussed technologies in pharmaceutical manufacturing, especially in cell and gene therapy (C/G), ATMPs, and other high-value small-batch applications.

The motivation behind these systems is absolutely understandable. Removing the operator from the aseptic core process reduces one of the biggest contamination risks in pharmaceutical manufacturing: the human factor.

At the same time, many of these therapies require extremely high product protection and, in some cases, significant operator protection. Nobody wants operators exposed to genetically modified cells, viral vectors, highly potent biological material, or radiopharmaceutical compounds.

From that perspective, the industry direction is logical and technically impressive. However, one misconception is starting to appear more frequently: The assumption that robotics, gloveless systems, or fully closed isolators automatically result in Annex 1 compliance or inherently superior contamination control.

Reality is more complex.

Robotics Do Not Automatically Solve Contamination Control

Modern robotic fill/finish systems are often presented as the next evolutionary step in aseptic processing. And in some applications, they absolutely are. But robotics alone do not eliminate contamination risk.

In practice, large robotic systems introduce an entirely new level of complexity into aseptic manufacturing environments, including airflow interaction, first-air disturbances, turbulence caused by movement and speed, difficult intervention concepts, telemanipulation challenges, maintenance and recovery strategies, as well as cleaning and biodecontamination complexity.

In addition, routine environmental monitoring can become more challenging in fully closed isolator systems. Activities such as surface swab sampling on critical and hard-to-reach locations may be more difficult to execute than in conventional systems. Access limitations, sampling procedures, and the need to maintain barrier integrity throughout the monitoring process can introduce additional operational complexities that must be considered during process design and validation.

Especially inside isolators, large robotic movements can significantly influence airflow behavior. In many cases, computational fluid dynamics (CFD) simulations and smoke studies become even more critical than in conventional systems.

A robotic arm moving dynamically through a Grade A environment is not automatically less risky than a well-controlled manual intervention. It simply introduces different risks, and those risks must be understood, tested, and controlled.

The same applies to gloveless systems. Removing gloves may reduce direct operator interaction and contamination risks, but it also shifts the entire process dependency toward automation reliability, software stability, sensor technology, motion control, and recovery concepts. That is not necessarily easier. It is simply a different form of complexity.

The Technology Is Impressive But Also Expensive

Many of the current gloveless robotic systems are highly sophisticated engineering achievements. But they are also extremely expensive. Complete robotic fill/finish systems for advanced therapies can easily reach investment levels of several million dollars, in some cases approaching or exceeding $10 million depending on complexity, containment requirements, and batch handling concepts.

Of course, the argument is often made that some therapies themselves may cost hundreds of thousands or even millions of dollars per patient. Therefore, the highest possible level of protection is justified. That argument is valid. However, the high value of a therapy should not automatically lead to the assumption that equally large budgets are available for fill/finish infrastructure and automation, especially during R&D, preclinical development, clinical trial phases, or even early commercial manufacturing.

The development, clinical progression, and regulatory approval of advanced therapies already consume enormous financial resources long before large-scale commercial manufacturing becomes reality. As a result, many organizations still rely on more compact, semi-automated, or flexible aseptic manufacturing solutions rather than highly complex fully robotic systems.

The important point is: High investment alone should not be confused with operational maturity.

Regulatory Expectations Are Still Evolving

One reality often overlooked in discussions around gloveless systems is that regulatory expectations and long-term operational experience are still evolving. Authorities are generally supportive of technologies that improve contamination control and reduce operator intervention. But at the same time, regulators still expect robust scientific justification, reproducibility, and operational consistency. And this is where many of the newer concepts are still building industrial experience.

In reality, many products in the C/G and ATMP space are still filled using comparatively conventional approaches such as biological safety cabinets (BSCs), table-top filling systems, compact isolators, and semi-automated solutions. Especially in early-stage clinical manufacturing and R&D environments, highly flexible smaller-scale systems often remain more practical than large fully robotic installations.

This does not mean robotics are failing. It simply reflects the current reality of the industry.

Today’s Large Robotic Systems May Represent A Transitional Phase

From a long-term technology perspective, it is difficult to imagine that the future of aseptic manufacturing will permanently rely on increasingly larger and more complex robotic systems operating inside massive isolators. The current generation of robotic gloveless systems may ultimately represent a transitional phase in the evolution of aseptic processing. The direction of the industry increasingly points toward smaller modular systems, smart handling units, highly specialized automation, decentralized manufacturing concepts, and patient-specific production.

Instead of one large centralized production line manufacturing massive commercial batches, future systems may focus more on flexible micro-manufacturing environments capable of producing very small quantities for highly individualized therapies. In some future scenarios, batch sizes may only consist of a few syringes, several vials, a single IV bag, or even one dose for one patient.

This changes the entire philosophy of pharmaceutical manufacturing. Under those conditions, the automation concepts of the future may look very different from today’s large robotic cells. Instead of complex multi-axis robotic systems moving continuously through isolators, future systems may rely more on compact, application-specific automation modules designed around very narrow process tasks. Smaller systems may ultimately provide simpler airflow concepts, reduced turbulence, easier biodecontamination, less intervention complexity, lower facility integration challenges, and potentially better scalability for decentralized manufacturing.

Hybrid concepts will likely establish themselves first as an intermediate step between fully manual and fully autonomous systems. The industry will not immediately and completely shift toward gloveless and fully closed systems across all types of pharmaceutical manufacturing.

In reality, many future aseptic processes may continue to include manual interventions, but those will be significantly reduced, highly controlled, and limited to strategically relevant operations where human flexibility still provides operational advantages. At the same time, in applications where the product requires the highest possible level of protection, and where budgets allow it, the industry will certainly continue to see increasing adoption of highly sophisticated closed isolator systems. This may ultimately result in hybrid concepts combining compact automation, selective robotic handling, reduced glove interventions, and highly focused operator interaction rather than completely human-free manufacturing environments.

From an operational perspective, these hybrid approaches may currently offer a more realistic balance between flexibility, complexity, contamination control, and industrial practicality.

The Human Factor Is Still Not Fully Eliminated

One important reality also remains: Even in highly automated gloveless systems, humans do not disappear completely. Operators still maintain systems, recover faults, manage materials, clean equipment, execute batch setup, perform environmental monitoring, and handle deviations.

The contamination risk is therefore not removed. It is redistributed.

Some of the most successful aseptic concepts are not necessarily the most technologically advanced. Often, they are the systems that best balance automation, simplicity, robustness, operational practicality, and contamination control strategy.

Technology alone is rarely the deciding factor.

What Does This Mean In Practice?

Robotics and gloveless isolators are important and promising technologies. In many applications, especially highly potent compounds, patient-specific therapies, and radiopharmaceutical or nuclear medicine applications, they may become increasingly necessary.

The direction itself is absolutely understandable: reduce unnecessary human interaction, improve containment, improve product protection, and increase process consistency. But robotics and closed systems alone are not a guarantee for Annex 1 compliance.

The real challenge remains exactly the same: understanding contamination risk and controlling it consistently across the entire process. The future of aseptic manufacturing will likely become more automated, more flexible, and more individualized. Whether that future is dominated by large robotic systems or by smaller specialized smart automation units remains to be seen. Most likely, the answer will be somewhere in between.

About The Author:

Juergen M. Metzger is founder and principal of Pharma-Technology-Consulting, LLC, specializing in aseptic fill/finish, containment systems, and Annex 1 compliance. He has nearly 30 years of experience in the pharmaceutical manufacturing industry, with a focus on isolator technology, aseptic processing, and contamination control strategies. He began his career with Bosch Packaging Technology in 1999 and has held technical and leadership roles across engineering, product management, business development, and global project coordination. He has worked extensively on aseptic fill/finish systems worldwide, supporting the design, implementation, and optimization of complex manufacturing environments. Over the course of his career, he has also served in director-level and strategic advisory roles focused on new technologies, market development, turnkey projects, and aseptic manufacturing strategy across the Americas and international markets.